A series of interesting enzymes were discovered during investigations on the degradation of quinoline by microorganisms. These include the molybdenum-containing hydroxylases that catalyze the transformation 1→2 and the unusual 2,4-dioxygenases that catalyze the reaction 3→4. The application of the hydroxylases may even be interesting in industry, because several quinoline derivatives are used as pharmaceuticals or agrochemicals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/(SICI)1521-3773(19980316)37:5<576::AID-ANIE576>3.0.CO;2-L | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrations.
Sci Rep
January 2025
Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706, Santiago de Compostela, Spain.
Aripiprazole (ARI) is an atypical antipsychotic which is a substrate of P-glycoprotein (P-gp), a transmembrane glycoprotein that plays a crucial role in eliminating potentially harmful compounds from the organism. ARI once-monthly (AOM) is a long-acting injectable form which improves treatment compliance. Genetic polymorphisms in ABCB1 may lead to changes in P-gp function, leading to individual differences in drug disposition.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) treatment remains to be a challenge; this is due to the fact that the pathogenesis of the disease is very complicated and not well understood. Unquestionable is the fact that the pathological hallmarks of AD are accumulation of amyloid plaques, neurofibrillary tangles and mitochondrial dysfunction all leading to neuronal cell death. Mitochondrial dysfunction plays an important role in AD.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Cognition Therapeutics, Inc, Pittsburgh, PA, USA.
Background: The sigma-2 receptor (S2R) modulator CT1812 is a first-in-class investigational therapeutic, currently in Phase 2 clinical trials for Alzheimer's disease (AD). Preclinical and clinical studies have shown that CT1812 displaces Aβ oligomers from synapses and clears them from the brain into the cerebrospinal fluid, restoring cognitive performance in a transgenic mouse model of AD. To investigate the mechanism of action of CT1812 and enable biomarker discovery, a phosphoproteomic analysis of CSF samples from SHINE-A was performed.
View Article and Find Full Text PDFAlzheimer's Imaging Consortium.
Alzheimers Dement
December 2024
CYRIC, Tohoku University, Sendai, Japan.
Background: Reactive astrogliosis refers to functional and morphological changes in astrocytes that occur with neuronal damage in numerous neurological conditions. PET tracers targeting monoamine oxidase B (MAO-B) are used to visualize reactive astrogliosis in the living brain. [18F]SMBT-1, a MAO-B selective PET tracer, was developed by modifying the chemical structure of [18F]THK5351.
View Article and Find Full Text PDFAlzheimer's Imaging Consortium.
Alzheimers Dement
December 2024
University of Pittsburgh, Pittsburgh, PA, USA.
Background: Tau-PET tracers have been used to diagnose and stage Alzheimer's disease. However, different tau tracers present distinct patterns of binding throughout the brain, challenging the harmonization of their results. We hypothesize that the choice of a reference region can impact the harmonization of the tau-PET standardized uptake value ratio (SUVR).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!